EA201401286A1 - Композиции и способы для лечения синдрома раздраженной толстой кишки с помощью 5-аминосалицилата - Google Patents

Композиции и способы для лечения синдрома раздраженной толстой кишки с помощью 5-аминосалицилата

Info

Publication number
EA201401286A1
EA201401286A1 EA201401286A EA201401286A EA201401286A1 EA 201401286 A1 EA201401286 A1 EA 201401286A1 EA 201401286 A EA201401286 A EA 201401286A EA 201401286 A EA201401286 A EA 201401286A EA 201401286 A1 EA201401286 A1 EA 201401286A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
syndrome
aminosalicilate
methods
infected
Prior art date
Application number
EA201401286A
Other languages
English (en)
Inventor
Эноч Борти
Уилльям Форбес
Original Assignee
Др. Фальк Фарма Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49621801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201401286(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Др. Фальк Фарма Гмбх filed Critical Др. Фальк Фарма Гмбх
Publication of EA201401286A1 publication Critical patent/EA201401286A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

В заявке описаны композиции и соответствующие способы, предназначенные для лечения желудочно-кишечных нарушений с использованием гранулированной формы месаламина. В некоторых вариантах осуществления изобретения желудочно-кишечное нарушение, подлежащее лечению, представляет собой синдром раздраженной толстой кишки (IBS). В некоторых вариантах осуществления изобретения желудочно-кишечное нарушение, подлежащее лечению, представляет собой IBS с преобладанием диареи (d-IBS).
EA201401286A 2012-05-19 2013-03-15 Композиции и способы для лечения синдрома раздраженной толстой кишки с помощью 5-аминосалицилата EA201401286A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649268P 2012-05-19 2012-05-19
US201261682154P 2012-08-10 2012-08-10
PCT/US2013/031848 WO2013176763A1 (en) 2012-05-19 2013-03-15 Compositions and methods for treatment of irritable bowel syndrome with 5-aminosalicylate

Publications (1)

Publication Number Publication Date
EA201401286A1 true EA201401286A1 (ru) 2015-04-30

Family

ID=49621801

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201401286A EA201401286A1 (ru) 2012-05-19 2013-03-15 Композиции и способы для лечения синдрома раздраженной толстой кишки с помощью 5-аминосалицилата

Country Status (13)

Country Link
US (1) US20130316000A1 (ru)
EP (1) EP2849565A4 (ru)
JP (1) JP2015517521A (ru)
CN (1) CN104394691A (ru)
AU (1) AU2013266857B2 (ru)
CA (1) CA2873855A1 (ru)
CL (1) CL2014003144A1 (ru)
EA (1) EA201401286A1 (ru)
IL (1) IL235640A0 (ru)
MX (1) MX2014013719A (ru)
NZ (1) NZ702643A (ru)
WO (1) WO2013176763A1 (ru)
ZA (1) ZA201407975B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
MX2016014624A (es) * 2014-05-09 2017-05-25 Nogra Pharma Ltd Metodos para el tratamiento de enfermedad inflamatoria del intestino.
CN110038017A (zh) * 2018-01-16 2019-07-23 重庆医科大学 5-氨基水杨酸的新用途
CN111905111B (zh) * 2020-09-16 2023-03-31 地奥集团成都药业股份有限公司 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法
WO2023102491A1 (en) * 2021-12-01 2023-06-08 Invea Therapeutics, Inc. Methods for treating gastrointestinal inflammatory disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016214A1 (en) * 1991-03-15 1992-10-01 Norwich Eaton Pharmaceuticals Inc. The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
WO2008085484A2 (en) * 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
US8865688B2 (en) * 2008-10-03 2014-10-21 Dr. Falk Pharma Gmbh Compositions and methods for treatment of bowel diseases with granulated mesalamine
JP2013509593A (ja) * 2009-10-30 2013-03-14 ネステク ソシエテ アノニム 過敏性腸症候群の診断方法

Also Published As

Publication number Publication date
IL235640A0 (en) 2015-02-01
CL2014003144A1 (es) 2015-07-17
MX2014013719A (es) 2015-02-10
ZA201407975B (en) 2015-11-25
EP2849565A1 (en) 2015-03-25
AU2013266857B2 (en) 2016-02-11
JP2015517521A (ja) 2015-06-22
NZ702643A (en) 2016-06-24
EP2849565A4 (en) 2016-03-23
US20130316000A1 (en) 2013-11-28
CA2873855A1 (en) 2013-11-28
CN104394691A (zh) 2015-03-04
WO2013176763A1 (en) 2013-11-28
AU2013266857A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201591786A1 (ru) Монотерапия gla для применения в лечении рака
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201590987A1 (ru) Соединения и способы их применения
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA202193044A2 (ru) Способы лечения таупатии
EA201890411A1 (ru) Терапевтически активные соединения и способы их применения
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201391332A1 (ru) Лиганды опиоидных рецепторов и способы их применения и получения
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201590997A1 (ru) Соединения и способы их применения
EA201792465A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
EA201790882A1 (ru) Способы и композиции для терапии рака печени
EA201690728A1 (ru) Применение молекул, связывающих семафорин-4d, для лечения атеросклероза
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201491500A1 (ru) Способы лечения фиброза
EA201291329A1 (ru) Гетероциклические соединения, их получение и их терапевтическое применение